delgocitinib · Leo Pharma As · NDA 219155
Anzupgo
Earliest generic entry, as listed
19 Sep 2031
Blocked by patent: US 8609647.
Listed patents · 1 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 8609647 | drug substance, drug product, use U-4237 · sets the listed date | 19 Sep 2031 |
Exclusivities · 1 unexpired
| NCE | new chemical entity (5 years) | 23 Jul 2030 |
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 219155 · 001 · RLD | cream, topical | 2% | 19 Sep 2031 |